Skip to content

Author

Yonghwan Park

We have 4 of 42 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Physical Activity and Cardiovascular Risk in Type 2 Diabetes With Normal Body Mass Index and Abdominal Obesity: A Nationwide Cohort Study.

BACKGROUND The prognostic implications of abdominal obesity and moderate-to-vigorous physical activity (MVPA) in patients with type 2 diabetes who have a normal body mass index remain unclear. METHODS This nationwide retrospective cohort study included 323 029 adults with newly diagnosed type 2 diabetes and a normal...

O. Kim, Yonghwan Park, Sooyeon Kim et al. · 0 citations
Open access Sep 2026

Clopidogrel monotherapy versus aspirin monotherapy in females and males after percutaneous coronary intervention: a sex-stratified analysis of the SMART-CHOICE 3 trial.

In patients with remote PCI and a high risk of recurrent ischaemic events, clopidogrel monotherapy showed a directionally consistent reduction in the composite endpoint of all-cause death, myocardial infarction, or stroke compared with aspirin in both females and males, supporting the consistency of the treatment effec...

Woo-Duk Kwon, Ki H. Choi, Yonghwan Park et al. · 0 citations
Aug 2026

Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.

Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months.

Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee et al. · 0 citations
Review Aug 2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.

J. Silvain, Ki H. Choi, Victorien Monguillon et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.